MINK THERAPEUTICS, INC. Share Price Today: Live Updates & Key Insights
MINK THERAPEUTICS, INC. share price today is $9.34, up -3.39%. The stock opened at $9.47 against the previous close of $9.74, with an intraday high of $9.52 and low of $9.34.
MINK THERAPEUTICS, INC. Share Price Chart
MINK THERAPEUTICS, INC.
MINK THERAPEUTICS, INC. Share Price Performance
MINK THERAPEUTICS, INC. Institutional Holdings
MINK THERAPEUTICS, INC. Market Status
MINK THERAPEUTICS, INC. Fundamentals
Market Cap 44.17 M
PB Ratio 11.3268
PE Ratio 0.0
Enterprise Value 35.57 M
Total Assets 5.72 M
Volume 28289
MINK THERAPEUTICS, INC. Company Financials
About MINK THERAPEUTICS, INC. & investment objective
Company Information MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab plus balstilimab with ramucirumab and paclitaxel for patients with previously treated, advanced esophageal, gastric, or gastro-esophageal junction adenocarcinoma; Phase 1 trial as a monotherapy in combination with anti-PD-1 checkpoint inhibitors, pembrolizumab, and nivolumab for refractory solid tumor cancers; and Phase 1 trial for the treatment of moderate to severe viral acute respiratory distress syndrome. It is also developing MiNK-215, an IL-15 armored tumor stromal targeting the FAP-CAR-iNKT program to treat solid tumors and inflammation; and MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen for auto-immune diseases. The company has collaborations with Autonomous Therapeutics to target and treat metastatic tumors; ImmunoScape, Inc. to discover and develop T-cell receptor therapies against targets in solid tumors; and C-Further for the development of PRAME-targeted iNKT cell therapy for pediatric cancers. The company was formerly known as AgenTus Therapeutics, Inc. and changed its name to MiNK Therapeutics, Inc. in June 2021. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
Organisation Biotechnology
Employees 23
Industry Biotechnology
CEO Dr. Jennifer S. Buell Ph.D.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:
Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*
Take your next step
MINK THERAPEUTICS, INC. FAQs
What is the share price of MINK THERAPEUTICS, INC. today?
The current share price of MINK THERAPEUTICS, INC. is $9.34.
Can I buy MINK THERAPEUTICS, INC. shares in India?
Yes, Indian investors can buy MINK THERAPEUTICS, INC. shares by opening an international trading and demat account with Motilal Oswal.
How to buy MINK THERAPEUTICS, INC. shares in India?
You can easily invest in MINK THERAPEUTICS, INC. shares from India by:
- Direct Investment:
Opening an international trading account with Motilal Oswal which includes KYC verification in the US. Your account gets activated in a few minutes to a few hours, after which you can start adding funds in USD balance to buy MINK THERAPEUTICS, INC. shares. - Indirect Investment:
Under this form of investment, you can choose either a Mutual Fund (MF) or an Exchange-Traded Fund (ETF) that invests in global shares and start investing in shares of MINK THERAPEUTICS, INC..
Can I buy fractional shares of MINK THERAPEUTICS, INC.?
Yes, many platforms allow you to buy fractional shares starting from as low as $1.
What is the market capitalization value of MINK THERAPEUTICS, INC.?
MINK THERAPEUTICS, INC. has a market cap of $44.17 M.
In which sector does MINK THERAPEUTICS, INC. belong?
MINK THERAPEUTICS, INC. operates in the Biotechnology sector.
What documents are required to invest in MINK THERAPEUTICS, INC. stocks?
To invest, you typically need:
What is the PE and PB ratio of MINK THERAPEUTICS, INC.?
The PE ratio of MINK THERAPEUTICS, INC. is N/A and the PB ratio is 11.33.